Though it's still struggling with data integration, Detroit's Henry Ford Health System is standardizing workflows and beginning to measure outcomes.
Researchers analyzed HERBY trial data to uncover a subgroup of patients with MAPK pathway alterations who had increased overall survival.
The analysis of HER2 and HER3 mutation carriers emphasizes how these studies can lead both to broadening and to narrowing of the patient populations for targeted drugs.
A Mount Sinai team performed targeted sequencing on non-small cell lung cancer samples to find mutations with clinical implications.
The changes include recommendations for first line immunotherapy in patients with high PD-L1 expression, and clarification on use of targeted therapies.
ASCO said MammaPrint should be used to inform decisions on withholding chemotherapy for these clinically high risk, HR-positive, HER2-negative breast cancers.
Some aspects of testing practice seem clear, while others present significant challenges for clinicians, according to discussions at the recent ASCO meeting.
The recent failure of Bristol-Myers Squibb's lung cancer immunotherapy to meet its primary endpoint demonstrates the challenge of working with imperfect biomarkers.
Data from the meeting suggest that lung cancer patients with ALK-positive tumors may soon have two first-line options and more choices when their disease progresses.
Repeat molecular analysis of a patient's cancer helped clinicians guide targeted therapies as drug resistance emerged and ebbed.